SFA Therapeutics Completes Key Phase 1b Trial Enrollment for Psoriasis Treatment

sfa therapeutics

JENKINTOWN, PA — SFA Therapeutics, Inc. recently announced the completion of patient enrollment for cohort 2 in its Phase 1b clinical trial of SFA-002, aimed at treating mild-to-moderate chronic plaque psoriasis. This marks a significant step in evaluating the safety and efficacy of the new treatment.

“This clinical milestone is essential to our ongoing evaluation of the safety and efficacy of SFA-002 for the treatment of psoriasis,” said Dr. Stefan Weiss, Chief Medical Officer of SFA Therapeutics. He noted that SFA-002, an endogenous biosynthetic compound, targets multiple pathways and offers the potential for greater efficacy with fewer side effects.

As the Phase 1b trial nears its conclusion, the company anticipates moving into Phase 2 studies later this year. “We look forward to entering Phase 2 studies in the second half of the year,” said Ira Spector, CEO of SFA Therapeutics. He highlighted that early results from cohort 1 show promise for SFA-002 as a successful treatment for psoriasis. The company expects additional data readouts from both cohorts in the coming months.

Previously, SFA Therapeutics reported positive results from cohort 1 of the Phase 1b trial. In 14 evaluable subjects with difficult-to-treat scalp and palmoplantar psoriasis, 92% showed a PASI improvement of over 50%. Additionally, 72% experienced an improvement greater than PASI 75, and two subjects achieved complete clearance with PASI 100. No related adverse events or toxicities were observed, and there were no rebound effects during the treatment period and follow-up.

SFA-002’s development shows promise for significantly improving the quality of life for patients with psoriasis. As the company prepares for the next phase of trials, the medical community and patients alike await further developments with keen interest.

READ:  Firstrust Bank Launches "Make Camp Happen" to Support Children with Disabilities

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.